IL134393A0 - Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues - Google Patents

Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues

Info

Publication number
IL134393A0
IL134393A0 IL13439398A IL13439398A IL134393A0 IL 134393 A0 IL134393 A0 IL 134393A0 IL 13439398 A IL13439398 A IL 13439398A IL 13439398 A IL13439398 A IL 13439398A IL 134393 A0 IL134393 A0 IL 134393A0
Authority
IL
Israel
Prior art keywords
disseminated
diagnosis
tissues
difficult
treatment
Prior art date
Application number
IL13439398A
Other languages
English (en)
Original Assignee
Inst Nat Sante Rech Med
Idm Immuno Designed Molecules
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Idm Immuno Designed Molecules filed Critical Inst Nat Sante Rech Med
Publication of IL134393A0 publication Critical patent/IL134393A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
IL13439398A 1997-09-05 1998-08-31 Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues IL134393A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/924,830 US20020068048A1 (en) 1997-09-05 1997-09-05 Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
PCT/EP1998/005707 WO1999013054A2 (en) 1997-09-05 1998-08-31 Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues

Publications (1)

Publication Number Publication Date
IL134393A0 true IL134393A0 (en) 2001-04-30

Family

ID=25450795

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13439398A IL134393A0 (en) 1997-09-05 1998-08-31 Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues

Country Status (7)

Country Link
US (2) US20020068048A1 (https=)
EP (1) EP1009806A2 (https=)
JP (1) JP2001515713A (https=)
AU (1) AU752676B2 (https=)
CA (1) CA2300387A1 (https=)
IL (1) IL134393A0 (https=)
WO (1) WO1999013054A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4544600A (en) * 1999-04-06 2000-10-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
DK1229940T3 (da) * 1999-11-15 2014-08-18 Piramal Healthcare Canada Ltd Temperaturstyret og ph-afhængig selvgelerende, vandig biopolymeropløsning
HK1052645B (en) * 2000-04-14 2008-03-20 Universtiy Of Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
WO2002040070A2 (en) * 2000-11-15 2002-05-23 Bio Syntech Canada Inc. Method for restoring a damaged or degenerated intervertebral disc
MXPA05005051A (es) 2002-11-12 2006-03-10 Albert B Deisseroth Vacuna de vector adenoviral.
CN103230415B (zh) * 2003-04-25 2016-05-04 匹兹堡大学联邦制高等教育 用于促进和增强神经修复和再生的肌肉来源的细胞（mdc）
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
AU2004249172A1 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
RU2006144851A (ru) 2004-06-15 2008-06-20 Бакстер Интернэшнл Инк. (Us) Применение терапевтических средств ex-vivo в виде твердых микрочастиц
CA2672936A1 (en) * 2006-11-30 2008-06-05 Bio Syntech Canada Inc. Method for in situ solidification of blood-polymer compositions for regenerative medicine and cartilage repair applications
RU2496482C2 (ru) 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Композиции и способы для доставки лекарственных средств
AU2009282619B2 (en) * 2008-08-18 2015-08-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
GB201504251D0 (en) * 2015-03-13 2015-04-29 Virttu Biolog Ltd And University Of Sheffield The Oncolytic herpes simplex virus infected cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
FR2729570A1 (fr) * 1995-01-24 1996-07-26 Idm Immuno Designed Molecules Procede de preparation de macrophages actives, trousses et compositions pour la mise en oeuvre de ce procede

Also Published As

Publication number Publication date
US20050048039A1 (en) 2005-03-03
CA2300387A1 (en) 1999-03-18
AU9441098A (en) 1999-03-29
EP1009806A2 (en) 2000-06-21
AU752676B2 (en) 2002-09-26
WO1999013054A2 (en) 1999-03-18
WO1999013054A3 (en) 1999-05-06
JP2001515713A (ja) 2001-09-25
US20020068048A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
GB2351911B (en) System to provide medical electrical stimulation to nervous tissue
ZA96740B (en) Skin treatment composition
PL351328A1 (en) Liquid compositions containing an agent beneficial for human skin
AUPQ302899A0 (en) Implants for the use in the treatment of aneurysmal disease
AU2039800A (en) 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins
IL134393A0 (en) Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
HUP0101913A3 (en) Immortalised cell lines derived from normal human skin tissues
HUP0104963A3 (en) Compositions for the treatment of skin diseases
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
PL336760A1 (en) Treatment of skin diseases
GB2361872B (en) Diagnosis of medical disorders
HUP0104568A3 (en) Human prostatic cell lines for cancer treatment
GB9704807D0 (en) Gel for application to the human or animal body
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
GB9510162D0 (en) Compositions for the treatment of skin conditions
EP1107778A4 (en) TREATMENT OF DISEASE CONDITIONS
IL125698A0 (en) Method for treatment of invasive cells
GB2340939B (en) Improvements in or relating to diagnosis of disease
HU9700079D0 (en) Topical compositions for the treatment of skin disease
HUP9800272A3 (en) Use of penciclovir for the treatment of human herpes-virus-8
ID28817A (id) Penggunaan turunan-turunan tetrahidropiridin (atau4-hidropiperidin)-butilazol dalam pembuatan obat untuk perawatan nyeri
GB9812290D0 (en) Back pain diagnosis
ZA9610264B (en) Preparation for use in the treatment of skin disorders.
AUPP715198A0 (en) The use of banana components in the treatment of various skin conditions
GB9925414D0 (en) Improvements in or relating to the investigation of skin histology